Press Enter to search · Esc to close
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.
The dual GIP/GLP-1 agonist is moving past weight loss into lipid repair and intracranial pressure relief. But a small case series flags a risk off-label users haven't been warned about.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
A fresh systematic review consolidates the perioperative signals — delayed gastric emptying, hypoglycemia, anesthesia risk — that every patient on a GLP-1 should bring up before surgery.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.